Crossmark

Extracorporeal photopheresis (ECP) in the treatment of chronic lung allograft dysfunction (CLAD): a prospective, multicentre, open-label, randomised controlled trial studying the addition of ECP to standard care in the treatment of bilateral lung transplant patients with CLAD (E-CLAD UK)

Crossref DOI link: https://doi.org/10.1136/bmjresp-2023-001995

Published Online: 2024-05-09

Published Print: 2024-05

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Fisher, Andrew J https://orcid.org/0000-0003-4822-7223
White, Michael https://orcid.org/0000-0002-3465-0592
Goudie, Nicola

Kershaw, Anneka

Phillipson, Julia

Bardgett, Michelle

Lally, Joanne

Bevin-Nicholls, Alex

Chadwick, Thomas

Bryant, Andrew

Russell, Sian

Smith, Hesther

Frisby, Laura

Errington, Rebecca

Carby, Martin

Thompson, Richard

Santhanakrishnan, Karthik

Parmar, Jasvir https://orcid.org/0000-0002-2710-0939
Lordan, James L

Vale, Luke

Hancock, Helen

Exley, Catherine

Gennery, Andrew R

Wason, James MS
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct10615985 at ClinicalTrials.gov

Documents that mention this clinical trial

Extracorporeal photopheresis (ECP) in the treatment of chronic lung allograft dysfunction (CLAD): a prospective, multicentre, open-label, randomised controlled trial studying the addition of ECP to standard care in the treatment of bilateral lung transplant patients with CLAD (E-CLAD UK)
https://doi.org/10.1136/bmjresp-2023-001995
Funding

Funding for this research was provided by:

Efficacy and Mechanism Evaluation Programme (NIHR130612)

Mallinckrodt Pharmaceuticals
License Information

License valid from 2024-05-09

Document is current

Any future updates will be listed below